Indian Irritable Bowel Syndrome drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 11.64% during the forecast period.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. Signs & symptoms include abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Treatment of irritable bowel syndrome consist of stress relief, change in diet, proper medicines, and counselling. Medications available for the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used for the treatment of irritable bowel syndrome, which include dicyclomine, peppermint oil, and hyoscyamine.
Market Growth Drivers
Rise in geriatric population, increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, surge in level of stress, and unhealthy diet are the major factors that drive the growth of the irritable bowel syndrome treatment market. In addition, increase in awareness programs regarding the treatment and management of irritable bowel syndrome and surge in inclination toward IBS products that enhance therapeutic outcome are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by the developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment that treat all the symptoms of the IBS disorder and high competition among the key players related to pricing are expected to restrain the growth of the market.